Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
Abstract Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2. Due to TNBC heterogeneity, clinical biomarkers and targeted therapies for t...
Main Authors: | Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-05-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-022-04855-0 |
Similar Items
-
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
by: Santiago Madera, et al.
Published: (2023-12-01) -
Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
by: Sho Ueno, et al.
Published: (2020-06-01) -
The role of protease activity in ErbB biology.
by: Blobel, C, et al.
Published: (2009) -
Spinal nerve injury causes upregulation of ErbB2 and ErbB3 receptors in rat dorsal root ganglia
by: Mizobuchi S, et al.
Published: (2013-02-01) -
Computational modeling of ErbB kinase oligomeric state.
by: Lim, Sing Mei.
Published: (2010)